Nexentis Technologies Inc. (NASDAQ:NXTS)
| Market Cap | 61.12K-89.4% |
| Revenue (ttm) | -66.00K-130.6% |
| Net Income | -16.03M-73.7% |
| EPS | -283.19+25.1% |
| Shares Out | 56.59K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 18,336,624 |
| Open | 1.14 |
| Previous Close | 1.39 |
| Day's Range | 0.94 - 1.19 |
| 52-Week Range | 0.94 - 32.90 |
| Beta | 1.86 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Dec 2, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About NXTS
Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems.The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Ness Ziona, Israel.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$NXTS stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in NXTS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by NXTS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
NXTS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New NXTS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to NXTS from public contracts
Source: USAspending.gov
NXTS Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from NXTS’s recent data — informational, not investment advice